Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-15 5:05 pm Sale | 13G | 4D Molecular Therapeutics Inc. FDMT | RA CAPITAL MANAGEMENT L.P. | 5,098,211 11.000% | -103,934 (-2.00%) | View |
| 2024-11-14 5:46 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | RA CAPITAL MANAGEMENT L.P. | 5,202,145 9.990% | 1,038,934 (+24.96%) | View |
| 2024-11-14 4:31 pm Sale | 13G | 4D Molecular Therapeutics Inc. FDMT | VIKING GLOBAL INVESTORS LP | 0 0.000% | -4,247,914 (Position Closed) | View |
| 2024-11-14 3:15 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 3,137,087 6.000% | 43,791 (+1.42%) | View |
| 2024-11-14 09:13 am Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | Deep Track Capital LP | 4,096,452 7.880% | 1,812,080 (+79.33%) | View |
| 2024-11-13 4:08 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 7,382,642 14.200% | 3,375,229 (+84.22%) | View |
| 2024-11-12 12:12 pm Unchanged | 13G | 4D Molecular Therapeutics Inc. FDMT | VANGUARD GROUP INC | 2,767,717 5.320% | 0 (Unchanged) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | 4D Molecular Therapeutics Inc. FDMT | BlackRock Inc. BLK | 4,868,789 9.400% | 0 (Unchanged) | View |
| 2024-11-06 6:07 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | GOLDMAN SACHS GROUP INC GS | 3,591,860 6.900% | 3,591,860 (New Position) | View |
| 2024-11-04 10:55 am Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | VANGUARD GROUP INC | 2,767,717 5.320% | 2,767,717 (New Position) | View |
| 2024-10-21 4:11 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | BlackRock Inc. BLK | 4,868,789 9.400% | 4,868,789 (New Position) | View |
| 2024-02-14 8:51 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | Venrock Healthcare Capital Partners III L.P. | 4,400,000 8.900% | 1,512,483 (+52.38%) | View |
| 2024-02-14 5:01 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | RA CAPITAL MANAGEMENT L.P. | 4,163,211 9.700% | 1,373,490 (+49.23%) | View |
| 2024-02-14 4:37 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | Kirn David | 2,033,069 4.700% | 10,571 (+0.52%) | View |
| 2024-02-14 09:56 am Unchanged | 13G | 4D Molecular Therapeutics Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.400% | 0 (Unchanged) | View |
| 2024-02-14 08:43 am Sale | 13G | 4D Molecular Therapeutics Inc. FDMT | Deep Track Capital LP | 2,284,372 5.340% | -372,529 (-14.02%) | View |
| 2024-02-13 10:56 am Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 3,093,296 7.200% | 1,627,029 (+110.96%) | View |
| 2024-01-25 4:59 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | BlackRock Inc. BLK | 3,464,587 8.100% | 955,955 (+38.11%) | View |
| 2024-01-08 4:15 pm Sale | 13G | 4D Molecular Therapeutics Inc. FDMT | VIKING GLOBAL INVESTORS LP | 4,247,914 9.900% | -540,000 (-11.28%) | View |
| 2024-01-08 4:05 pm Purchase | 13G | 4D Molecular Therapeutics Inc. FDMT | VIKING GLOBAL INVESTORS LP | 4,787,914 11.200% | 850,000 (+21.59%) | View |